Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER

Related

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024

• 

  Study of Comparative Treatments for REtinal Vein Occlusion 2 (SCORE2): Primary Results

  Ingrid U. Scott, MD, MPH

  Updates from the Field

  2017

• 

  Impact of Initial Monthly Doses of Aflibercept on Visual Outcomes in Eyes With Diabetic Macular Edema in Routine Clinical Practice in the US

  Ferhina S Ali, MD, MPH

  Annual Meeting Talks

  2023